MW

Markus Warmuth

Chief Executive Officer at Monte Rosa Therapeutics

Cambridge, Massachusetts

Investor
VC

Invests in

Stages:

Series A

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Biotechnology
Drug Discovery
Oncology
Cancer
Lifesciences
Pharmaceutical Industry
Molecular Biology
Drug Development
Genomics
High Throughput Screening
Biochemistry
Immunology
Clinical Development
Cell
Cell Biology
In Vitro
Cell Culture
Pharmacology
Antibodies
Assay Development

Education

Lists including Markus

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

Investments

Monte Rosa Therapeutics

Series A

Total Funding: $220M

Work Experience

VT
Ventus Therapeutics

2021

  • Member Board Of Directors

    2021

MR
Monte Rosa Therapeutics

2019

  • Chief Executive Officer

    2019

VV
Versant Ventures

2019

  • Venture Partner

    2019

II
IMV Inc.

2018 - 2023

  • Independent Board Member

    2018 - 2023

TR
Third Rock Ventures

2018 - 2019

  • Entrepreneur In Residence

    2018 - 2019

RT
Relay Therapeutics

2017 - 2018

  • Independent Board Member

    2017 - 2018

H3 Biomedicine

2011 - 2018

  • President and Chief Executive Officer

    2011 - 2018

  • Chief Scientific Officer

    2011 - 2011

NI
Novartis Institutes for BioMedical Research (NIBR)

2008 - 2011

  • Executive Director and Head of Oncology Drug Dicovery

    2008 - 2011

GI
Genomics Institute of the Novartis Research Foundation

2002 - 2008

  • Director Kinase Platform

    2002 - 2008

LU
Ludwig-Maximilians Universität München

1998 - 2002

  • MD

    1998 - 2002

    Medical Oncologist and Principal Investigator